Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

FTSV - Forty Seven Inc

Previous close
95.51
0   0%

Share volume: 0
Last Updated: Mon 06 Apr 2020 06:00:00 AM CEST
Pharmaceuticals: Major: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$95.51
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
30%
Profitability 28%
Dept financing 21%
Liquidity 41%
Performance 32%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$95.51
P/E Ratio 
N/A
DAY RANGE
$95.51 - $95.51
EPS 
-$2.47
52 WEEK RANGE
$5.53 - $95.52
52 WEEK CHANGE
$497.31
MARKET CAP 
4.599 B
YIELD 
N/A
SHARES OUTSTANDING 
48.156 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$38,940,146
AVERAGE 10 VOLUME 
$1,258,219
AVERAGE 30 VOLUME 
$2,816,220
Company detail
CEO:
Region: US
Website: http://www.fortyseveninc.com
Employees: 68
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceuticals: Major
Sector: Health Technology

Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.

Recent news